ARS Pharmaceuticals Stock Discussion

$ARS Pharmaceuticals (SPRY.US)$ comments from ALK CEO and sales projection. 🍾

$ARS Pharmaceuticals (SPRY.US)$
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products
ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales
ARS Pharma retains all U.S. rig...

$ARS Pharmaceuticals (SPRY.US)$ Showcases Intranasal Epinephrine Data At 2024 American College Of Allergy, Asthma & Immunology Annual Scientific Meeting, Friday October 25.

$ARS Pharmaceuticals (SPRY.US)$ soon SPRY will end the monopoly.

$ARS Pharmaceuticals (SPRY.US)$ hmmm I smell news….

$ARS Pharmaceuticals (SPRY.US)$
Reuters10/15/2024 13:04
ARS PHARMACEUTICALS- UNIT ENTERED SUPPLY AGREEMENT WITH NUOVA OMPI S.R.L. This is an Italian company and I’m assuming distribution in EU is in the near future 👏

$ARS Pharmaceuticals (SPRY.US)$  Eligible Patients to Pay $25 for Two Neffy Devices in USA, sales ready for EU market, Pfizer $300 EpiPen monopoly is over 👏

$ARS Pharmaceuticals (SPRY.US)$ ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
3 MINUTES AGO, 4:47 PM EDT
VIA GLOBENEWSWIRE
If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children
The submission of neffy 1 mg sNDA follows FDA approval on August 9, 2024, of neffy (2 mg) for the treatment of Type I Allergic Reactions, i...

$ARS Pharmaceuticals (SPRY.US)$ ARS Pharmaceuticals Launches Pre-Ordering Services for Neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis